ARS Pharmaceuticals, Inc. Investors Can Join Securities Fraud Lawsuit
Purchasers of ARS Pharmaceuticals, Inc. securities between March 9, 2026, and June 24, 2026, have an opportunity to join a securities fraud lawsuit. The deadline to be appointed lead plaintiff is October 5, 2026.
Rosen Law Firm, a global investor rights law firm, is reminding purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) of their opportunity to participate in a securities fraud lawsuit. The lawsuit pertains to purchases made during the period from March 9, 2026, through June 24, 2026.
The law firm urges investors who incurred losses on these purchases during the specified class period to contact them by the October 5, 2026, deadline. This date is critical for investors seeking to be appointed as lead plaintiff in the action.
Rosen Law Firm is investigating allegations that ARS Pharmaceuticals and its officers may have violated federal securities laws. While the specific nature of the allegations was not detailed in the original announcement, such lawsuits often involve claims of misleading statements or omissions of material facts to investors.